financetom
Business
financetom
/
Business
/
--CrowdStrike CEO Called to Testify Before US House Committee
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--CrowdStrike CEO Called to Testify Before US House Committee
Jul 23, 2024 5:49 AM

08:26 AM EDT, 07/23/2024 (MT Newswires) --

Price: 267.26, Change: +3.35, Percent Change: +1.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nvidia Fiscal Q3 Adjusted Earnings, Revenue Rise; Fiscal Q4 Revenue Outlook Set; Dividend Maintained
Nvidia Fiscal Q3 Adjusted Earnings, Revenue Rise; Fiscal Q4 Revenue Outlook Set; Dividend Maintained
Nov 19, 2025
04:26 PM EST, 11/19/2025 (MT Newswires) -- Nvidia ( NVDA ) reported fiscal Q3 adjusted earnings late Wednesday of $1.30 per diluted share, up from $0.81 a year earlier. Analysts polled by FactSet expected $1.26. Revenue for the three months ended Oct. 26 was $57.01 billion, up from $35.08 billion a year earlier. Analysts surveyed by FactSet expected $54.91 billion....
Nutrien selects US site for potash terminal
Nutrien selects US site for potash terminal
Nov 19, 2025
WINNIPEG, MANITOBA, Nov 19 (Reuters) - Nutrien ( NTR ), the world's largest potash fertilizer producer, said on Wednesday it is hoping to build a new export terminal in Longview, Washington, to meet rising demand for Saskatchewan-made potash. It expects to make a final investment decision on the idea in 2027. Previously Nutrien ( NTR ) said it was considering...
US FDA approves Bayer's drug for type of lung cancer
US FDA approves Bayer's drug for type of lung cancer
Nov 19, 2025
Nov 19 (Reuters) - The U.S. Food and Drug Administration on Wednesday said it has approved Bayer's drug for patients with a type of lung cancer that has advanced or spread despite previous treatments. The drug, branded as Hyrnuo, is approved for non-squamous non-small cell lung cancer (NSCLC) in patients with mutations affecting the HER2 protein, which plays a crucial...
Universal Technical Institute Fiscal Q4 Earnings Flat, Revenue Rises; Fiscal 2026 Outlook Set
Universal Technical Institute Fiscal Q4 Earnings Flat, Revenue Rises; Fiscal 2026 Outlook Set
Nov 19, 2025
04:23 PM EST, 11/19/2025 (MT Newswires) -- Universal Technical Institute ( UTI ) reported fiscal Q4 net income late Wednesday of $0.34 per diluted share, flat from $0.34 a year earlier. Analysts polled by FactSet expected $0.26. Revenue for the quarter ended Sept. 30 was $222.4 million, up from $196.4 million a year earlier. Analysts polled by FactSet expected $219.2...
Copyright 2023-2026 - www.financetom.com All Rights Reserved